MARKET WIREStocktwits • 23h ago
OKYO: Pharma Limited Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
Why OKYO Stock slipped -0.68% Today — RQD Quant Desk Flash
$1.46 -0.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.46
OKYO Pharma Limited (OKYO) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $77.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OKYO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OKYO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, OKYO Pharma Limited (NASDAQ: OKYO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.46 (-0.68% 1D, market cap $77.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OKYO ranks #281 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OKYO compare to ATRA and TNYA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OKYO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ATRA (Atara Biotherapeutics Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC 85.0%, cap $80.4M) and TNYA (Tenaya Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $83.7M). Among the 5-stock peer group, OKYO leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OKYO?
▼
For OKYO Pharma Limited (OKYO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #281 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.46 (-0.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OKYO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY OKYO SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.2M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.44-2.8% Next Q
41
Q2 (-2Q)Grade D$1.40+2.9% Next Q
44
Q3 (-1Q)Grade D$1.44+1.4% Next Q
46
CurrentGrade D$1.46-5.4% Hist 90D α
49
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OKYO Turnaround Squeeze
While OKYO currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.44) and Max Pain ($1.53) forces dealer call-delta covering toward $3.36.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OKYO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OKYO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OKYO Stock slipped -0.68% Today — RQD Quant Desk Flash
OKYO Pharma Limited (OKYO) slipped -0.68% to $1.46, trading at 10% of its 52-week range ($1.26 – $3.2). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 10% of its 52-week range ($1.26 – $3.2) with RSI-14 at 52.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.46 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $2.2M annual free cash flow.
Live OKYO Headlines & Catalysts
MARKET WIREThe Globe and Mail • 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)The Globe and Mail report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainGlobeNewswire report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain.Stock Titan report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Quantum BioPharma Ltd. (QNTM) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal PainQuiver Quantitative report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Neptune trial enrolls first patients for neuropathic corneal pain By Investing.comInvesting.com UK report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Cadrenal Therapeutics, Inc. (CVKD) Seasonal Returns ChartYahoo! Finance Canada report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OKYO)
- ✓Walkthrough of OKYO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OKYO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.10%▼ DESCENDING CHANNEL
2026-11-03O $1.50H $1.50L $1.46C $1.46VOL 107.5K
RES: $1.64SUP: $1.23SMA50: $1.44SMA200: $1.61
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OKYO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on OKYO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OKYO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OKYO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OKYO)
Health Care Rank #281 of 1015
⚔️ ATRA vs OKYO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OKYO vs. ATRA, TNYA, CRDF, NMRA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, OKYO Pharma Limited (OKYO) ranks #281 by composite RQD confidence (49/100, grade D) and #683 by equity capitalization ($77.1M). Within this direct 5-issuer industry benchmark cohort, OKYO leads on earnings valuation at N/A trailing P/E, while ATRA leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. OKYO currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OKYO
ACTIVE
OKYO Pharma Limited | D | 49/100 | — | — | — | -0.68% | $77.1M | Benchmark Subject |
| ATRA Atara Biotherapeutics Inc. | D | 49/100 | — | — | 85.0% | +5.87% | $80.4M | /atra-vs-okyo → |
| TNYA Tenaya Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -1.74% | $83.7M | /tnya-vs-okyo → |
| CRDF Cardiff Oncology Inc. | E | 25/100 | — | — | -35.0% | -5.09% | $69.2M | /crdf-vs-okyo → |
| NMRA Neumora Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +34.99% | $69.0M | /nmra-vs-okyo → |
2. OKYO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTOKYO Pharma Limited (OKYO) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $77.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. OKYO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OKYO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, OKYO Pharma Limited (NASDAQ: OKYO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.46 (-0.68% 1D, market cap $77.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OKYO ranks #281 in composite RQD confidence.
How does OKYO compare to ATRA and TNYA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OKYO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ATRA (Atara Biotherapeutics Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC 85.0%, cap $80.4M) and TNYA (Tenaya Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $83.7M). Among the 5-stock peer group, OKYO leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OKYO?
For OKYO Pharma Limited (OKYO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #281 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OKYO trading relative to its 50-day, 200-day, and 52-week technical levels?
OKYO last traded at $1.46 (-0.68% on volume of 91,930 shares), positioning the stock +1.39% above its 50-day simple moving average ($1.44) and -9.32% below its 200-day simple moving average ($1.61). Across its 52-week range of $1.26 to $3.20, OKYO sits at the 10.3% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.28 to $1.64).
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ SEC XBRL & RQD VERIFIED
OKYO — OKYO Pharma Limited: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
OKYO Pharma Limited (OKYO) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.46 (-0.68% 1D, market capitalization $77.1M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
OKYO Pharma Limited is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.1B. Per the news wire, the company is advancing urcosimod for neuropathic corneal pain through a Phase 3 pivotal trial, with first patients reported as enrolled.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $1.26 – $3.20 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Accordingly, no upstream or downstream dependencies, sector correlation mappings, or second-order bottlenecks can be identified from the source data. An investor should note that the clinical program's progress is the only substantive operational driver visible in the sources, but no supplier, partner, or manufacturing dependency is documented.
- Key Question #1: Can OKYO sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $3.20 52-week high?
- Key Question #3: How sensitive is OKYO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
OKYO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for OKYO Pharma Limited (OKYO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 23h ago
OKYO: Pharma Limited Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ) The Globe and Mail report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain GlobeNewswire report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. Stock Titan report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Quantum BioPharma Ltd. (QNTM) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain Quiver Quantitative report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Neptune trial enrolls first patients for neuropathic corneal pain By Investing.com Investing.com UK report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Cadrenal Therapeutics, Inc. (CVKD) Seasonal Returns Chart Yahoo! Finance Canada report covering OKYO Pharma Limited (OKYO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
OKYO Bull vs. Bear Conversation Board — What's Your Call at $1.46?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OKYO 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $1.72 (+17.0%)
📌 Pinned Debate First patients have enrolled in the Phase 3 pivotal trial of urcosimod, the company's principal clinical catalyst, and the balance shee
The street is overcomplicating OKYO Pharma Limited (OKYO). First patients have enrolled in the Phase 3 pivotal trial of urcosimod, the company's principal clinical catalyst, and the balance sheet pillar scores 13/20 with Altman Z 2.5 and Piotroski F 6/9.. With an RQD score of 49/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.59.
CapAlloc_Nerd 🐂 BULL
@MacroHawk_NYC Agree on the RQD 49/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.47 and keeping dry powder in case we test $1.37.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $1.12 (-23.8%)
Spot @ $1.47 The RQD rating is a Roarable Sell at 52/D+ with ROIC and FCF yield both at 0%, and the cash engine, flow, and insider pillars score 12,
Sitting on the sidelines or leaning short OKYO above $1.47. The RQD rating is a Roarable Sell at 52/D+ with ROIC and FCF yield both at 0%, and the cash engine, flow, and insider pillars score 12, 8, and 9 out of 20.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $3.20.